Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for Severe Asthma with ABPA
NCT04108962Phase 4Withdrawn
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Dec 2019
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of benralizumab in severe asthma and allergic bronchopulmonary aspergillosis (ABPA), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Number of steroid requiring exacerbations at 26 weeks. Planned start Dec 2019; status: withdrawn.
02
Drugs
benralizumab
03
Conditions
severe asthmaallergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT04108962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108962.